Pancreatic Cancer Research

ResearcherApex Therapeutics, Inc.Active in the last 2 years

Mark R. Kelley

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9472-1826; OpenAlex author ID A5062363713; NIH RePORTER profile ID 1899304. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 5)
Trials
0
Grants
3
Labs led
1
Collaborators
26
Papers, trials and grants by year

2012: 1 paper · 2013: 1 grant · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper, 1 grant · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 14

  1. Beyond Cys65: Redox Effector Factor-1 CRISPR-Engineered Cys93 and Cys99 Mutants Reveal Cooperative and Secondary Roles of Redox Signaling and Pancreatic Ductal… Co-author DOI 10.1177/15230864261489484↗
  2. Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer. Last author DOI 10.1186/s13046-026-03705-7↗
  3. Integrated Post-Translational Modification (PTM) Proteomics Reveals Early Redox and Mitochondrial Remodeling Following Ref-1 Inhibition in Pancreatic Cancer Last author DOI 10.2139/ssrn.7345898↗
  4. The absence of Peroxiredoxin-1 in human pancreatic ductal adenocarcinoma (PDAC) markedly reduces cell survival and tumor growth when coupled with the inhibitio… Last author DOI 10.1016/j.redox.2025.103848↗
  5. In vitro and In vivo evidence demonstrating chronic absence of Ref-1 Cysteine 65 impacts Ref-1 folding configuration, redox signaling, proliferation and metast… Last author DOI 10.1016/j.redox.2023.102977↗
  6. Combating PDAC Drug Resistance: The Role of Ref-1 Inhibitors in Accelerating Progress in Pancreatic Cancer Research. First author DOI 10.33696/signaling.5.126↗
  7. Gemcitabine plus nab-paclitaxel preserves skeletal and cardiac mass and function in a murine model of pancreatic cancer cachexia Co-author DOI 10.1101/2023.04.15.536434↗
  8. Activation of the integrated stress response (ISR) pathways in response to Ref-1 inhibition in human pancreatic cancer and its tumor microenvironment. Co-author DOI 10.3389/fmed.2023.1146115↗
  9. RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostas… Last author DOI 10.3389/fonc.2022.826617↗
  10. Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target. Co-author DOI 10.1186/s13046-021-02046-x↗
  11. Blocking HIF signaling via novel inhibitors of CA9 and APE1/Ref-1 dramatically affects pancreatic cancer cell survival. Co-author DOI 10.1038/s41598-018-32034-9↗
  12. APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequenci… Co-author DOI 10.1002/1878-0261.12138↗
  13. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-16-0253↗
  14. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. Co-author DOI 10.1371/journal.pone.0047462↗

Grants 3

  1. Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer R01CA282478↗
  2. Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations R01CA167291↗
  3. Novel Therapeutic Strategy for Refractory and Relapse Childhood Acute Leukemia R43CA171344↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Melissa L. Fishel · 13 shared papers, 2 shared grants, 2012–2026 · strength 3.98
  2. Silpa Gampala · 7 shared papers, 2021–2026 · strength 1.44
  3. Eyram K. Kpenu · 5 shared papers, 2023–2026 · strength 1.35
  4. Mahmut Mijit · 5 shared papers, 2022–2026 · strength 1.04
  5. Sanya Haiaty · 3 shared papers, 2025–2026 · strength 0.74
  6. Rajesh Sardar · 2 shared papers, 2026 · strength 0.51
  7. Fenil Shah · 3 shared papers, 2017–2021 · strength 0.27
  8. Sonia Kiran · 1 shared paper, 2025 · strength 0.23
  9. Nayela N. Chowdhury · 1 shared paper, 2024 · strength 0.20
  10. Martin F Haslanger · 1 shared grant, 2013 · strength 0.15
  11. Christian Schneeweis · 1 shared paper, 2022 · strength 0.15
  12. Zonera Hassan · 1 shared paper, 2022 · strength 0.15
  13. Daenique H. A. Jengelley · 1 shared paper, 2023 · strength 0.14
  14. Joseph E. Rupert · 1 shared paper, 2023 · strength 0.14
  15. Brittany R. Counts · 1 shared paper, 2023 · strength 0.14
  16. Xiaoling Zhong · 1 shared paper, 2023 · strength 0.14
  17. Ashok Narasimhan · 1 shared paper, 2023 · strength 0.14
  18. Teresa A Zimmers · 1 shared paper, 2023 · strength 0.14
  19. Derek P. Logsdon · 2 shared papers, 2016–2018 · strength 0.13
  20. Hye‐ran Moon · 1 shared paper, 2021 · strength 0.11
  21. Bumsoo Han · 1 shared paper, 2021 · strength 0.11
  22. Safi Shahda · 2 shared papers, 2012–2016 · strength 0.08
  23. Nicholas Joseph Zyromski · 1 shared paper, 2016 · strength 0.05
  24. Murray Korc · 1 shared paper, 2016 · strength 0.05
  25. Angelo A. Cardoso · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.